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Summary. Background: Patients with venous thromboembolism (VTE) are at risk of having a subsequent cancer diagnosis. The risk is highest during the first 6 months. Reports on cancer rates thereafter are controversial. We aimed to assess long-term rates and risk factors of cancer in patients with VTE. Methods and Results: We followed patients with a first unprovoked VTE after discontinuation of anticoagulation, and excluded those receiving long-term antithrombotic therapy or with major thrombophilia. The study endpoint was the occurrence of cancer. Sixty-two (5.2%) of 1188 patients developed cancer during a median follow-up of 98 months. The cumulative incidence rates of cancer were 0.7% (95% confidence interval [CI] 0.2-1.2%), 3.1% (95% CI 2.0-4.1%) and 9% (95% CI 6.5-11.5) after 1, 5 and 15 years; these were not significantly different from those in the matched general population (0.6%, 3.4%, and 12.2%, respectively). The corresponding standardized incidence ratios (ratio of the observed cancer cases and the number of cases based on national cancer incidence rates) of 1.1 (95% CI 0.5-2.5), 1.0 (95% CI 0.6-1.4) and 0.9 (95% CI 0.7-1.2) did not indicate a difference in cancer incidence between our cohort and the general population. Advancing age (hazard ratio [HR] per decade 1.5, 95% CI 1.2-2.0) and shorter duration of anticoagulation (HR per 1-month decrease 1.3, 95% CI 1.1-1.6) were associated with an increased cancer risk, whereas VTE recurrence was not (HR 1.17, 95% CI 0.66-2.07). Conclusions: Asymp
Introduction
The diagnosis of a venous thromboembolic event raises suspicion of an underlying malignancy. There is an increased likelihood of detecting an otherwise symptomless cancer not only at the time of the acute venous thromboembolism (VTE), but also for at least the first 6 months after this [1] [2] [3] [4] [5] . Whereas, in some cohorts, the cancer rates rapidly declined after 6 months, an increased risk continued for as long as 10 years in others [1, 3, 4, 6] . One reason for these discrepant findings may be the difference in diagnosing and reporting cancers, as some studies were large, population-based, and hospital recordbased, and some were smaller and observational. Another explanation could be the inclusion of patients with VTE secondary to a temporary risk factor, including surgery or immobilization, as the association between VTE and cancer is most pronounced in patients with an otherwise unprovoked thrombosis [7] .
An antitumor effect of antithrombotic drugs, including heparin, acetylsalicylic acid, and vitamin K antagonists, has been repeatedly reported but is still debated [8] . Case-control studies indicated that warfarin may be associated with a decreased incidence of cancer, but the cohorts were restricted to urogenital malignancies [9, 10] . Clinical trials in which patients with VTE were randomly assigned to different durations of anticoagulation gave disparate results regarding the long-term risk of cancer. Schulman et al. found a lower risk among patients treated with vitamin K antagonists for 6 months than among those treated for 6 weeks [5] . In the two Warfarin Optimal Duration of Anticoagulation Italian Trials, the incidence of newly diagnosed cancer was not reduced in patients with VTE receiving anticoagulation for 1 year as compared with patients treated for 3 months [11] .
In the present analysis, we used the dataset of a large cohort of patients with a first unprovoked VTE and a long-term follow-up to evaluate the course of their disease. We aimed to assess the incidence of newly diagnosed cancer after discontinuation of anticoagulation in a welldefined and homogeneous population of patients with VTE.
Methods

Patients
Between 1992 and September 2008, patients aged at least 18 years with a first unprovoked deep vein thrombosis of the leg and/or pulmonary embolism were enrolled in a multicenter cohort study (Austrian Study on Recurrent Venous Thromboembolism [AUREC]) after at least 3 months of anticoagulation with vitamin K antagonists. Study details have been previously described [12] . VTE unrelated to surgery, trauma, pregnancy or cancer was classified as unprovoked. We excluded patients who continued to receive antithrombotic therapy, had major defects on routine thrombophilia testing (deficiency of antithrombin, protein C, or protein S, homozygosity or double heterozygosity for factor V Leiden and/or prothrombin G20210A, or a lupus anticoagulant), or had developed cancer during anticoagulation for the initial VTE. The primary aim of the study was to evaluate the risk of recurrent VTE. First and recurrent VTE were objectively verified by ultrasound, venography, computed tomography, or ventilation/perfusion lung scanning, respectively.
Patients entered the study at the time of discontinuation of anticoagulation, and were followed until data were locked on 15 May 2015 for the present analysis. Venous blood for laboratory analysis was drawn 3 weeks after discontinuation of anticoagulation. The study endpoint for this analysis was the occurrence of histologically confirmed solid or hematologic malignant disease with the exception of non-melanoma skin cancer. Patients were seen at the study center every 3 months during the first year and every 12 months thereafter, when the investigator questioned them about the occurrence of cancer. One hundred and thirty-two of 294 patients with recurrent VTE discontinued their regular visits, and were sent questionnaires to obtain information on whether they had received a cancer diagnosis after recurrence. If there was a reported cancer, the diagnosis was validated by checking against medical records from the respective treating center. In the case of death, the cause was investigated by review of death certificates, hospital records, and autopsy reports. The study was approved by the local ethics committee, and all patients gave informed consent.
Statistical analysis
Continuous variables are reported as mean and standard deviation, and categorical variables as frequency and percentage. To investigate the contribution of each individual variable to the risk of developing cancer, univariable and multivariable Cox proportional hazards models were used. The latter contained all variables of interest. The proportional hazards assumption was assessed by evaluating the correlation of scaled Schoenfeld residuals with time. As standard estimates of Cox regression can be biased if the number of events is small, as in our study, we used Firth's correction to reduce possible bias in estimation [13] . The impact of missing data on this risk factor analysis was assessed with a multiple imputation approach. The analysis was repeated on 10 completed datasets, obtained from imputation by the use of chained equations. The results were then pooled by the use of Rubin's Rules to obtain the final effect and variance estimates [14, 15] . This serves as a sensitivity analysis to investigate whether the estimates differ drastically as compared with a complete case analysis.
Three parameters (hemoglobin, leukocyte count, and platelet count) were unavailable for patients included before 1998. These blood parameters did not show any effect on cancer risk in multivariable Cox analysis using only data from the subsample of patients recruited after 1998. They were therefore excluded from further analysis to minimize the number of predictors and avoid loss of precision resulting from imputation.
The cancer risk of the study population was compared with that of an age-matched and sex-matched reference population, based on official cancer incidence data collected by the Austrian Federal Statistics Agency from the general Austrian population in the year 2002 (median of inclusion year of study patients). The ratio of observed and expected cancers for each year after the study began (standardized incidence ratio [SIR]), the cumulative SIR, which accumulates the observed and expected cancers over time, and the expected survival distribution were computed with the methods outlined by Finkelstein et al. [16] .
The short-term effect of recurrent VTE on cancer risk was assessed by including recurrent VTE as a time-varying covariate in a Cox model. By different coding of early recurrent VTE (within 4 weeks after study inclusion) and later recurrent VTE, this model was also used to estimate differences in cancer risk between these two populations. To further investigate the role of recurrent VTE as a risk factor, an approach resembling a matched cohort study was used. For each patient with recurrence at follow-up time T, a control group of, at most, five patients of the same sex, with similar age and score based on the Vienna prediction model, was formed from the study data [17] . This selection was independent of whether the control patients had experienced a recurrent VTE or cancer diagnosis at a time later than T. Subsequently, the overall follow-up time of the case and control group was reduced by T to provide an identical starting point and to fairly assess the effect of the recurrent VTE on the risk of cancer. A Cox model was fitted on the modified data, stratified for each case-control group, and a robust covariance estimate was used to account for multiple observations per patient. Results were adjusted for duration of anticoagulation therapy. Other potential covariates were found to be adequately controlled for by the matching procedure.
All P-values of < 5% were considered to indicate statistical significance. Statistical analysis was carried out in R version 3.2.4, with the package mice being used to implement the multiple imputation procedure [15] .
Results
Risk of cancer
The baseline characteristics of 1188 patients with a first unprovoked VTE are shown in Table 1 . Their mean age was 49 years (range: 18-91 years), and 54% of them were women. Duration of anticoagulation, which was the time between the initial VTE and start of follow-up, was 7.2 months on average (range: 3-18 months).
During a median follow-up of 98 months (25th-75th percentile 48-140), 62 (5.2%) patients were diagnosed with cancer. Cancer types were heterogeneous, and comprised malignancies of the lung (n = 10), colon (n = 9), hematopoetic system (n = 9), breast (n = 7), prostate (n = 5), thyroid gland (n = 4), skin (n = 4), stomach/ esophagus (n = 4), bladder (n = 3), kidney (n = 2), and single other locations (n = 5).
Thirty-two of 1188 patients died during follow-up for reasons other than cancer: cardiac failure (n = 16), pulmonary embolism (n = 4), ischemic stroke (n = 2), intracranial bleeding, septicemia, suicide, senility (two each), asphyxia, or aortic dissection (one each). Ninetyone patients were lost to follow-up; the median time to loss to follow-up was 40 months (25th-75th percentile 13-87).
According to Kaplan-Meier estimates, the cumulative cancer incidence rates were 0.7% (95% confidence interval [CI] 0.2-1.2%), 1.8% (95% CI 1.0-2.6%), 3.1% (95% CI 2.0-4.1%) and 9% (95% CI 6.5-11.5%) at 1, 2, 5 and 15 years after discontinuation of anticoagulation, respectively; these were not significantly different from those in the matched general population (0.6%, 1.3%, 3.4%, and 12.2%, respectively) (Fig. 1) .
The corresponding cumulative SIRs, which are the ratios of the observed number of cancers in our study cohort and the expected number of cancers in the agematched and sex-matched general population accumulated over time, were 1.1 (95% CI 0.5-2.5), 1.4 (95% CI 0.8-2.3), 1.0 (95% CI 0.6-1.4), and 0.9 (95% CI 0.7-1.2). They did not indicate a significant difference in the cancer incidence between our study cohort and the matched general population (Fig. 2) .
Two hundred and thirty-seven patients had an initial distal vein thrombosis, and six of these developed cancer. The cumulative SIRs were 1.2 (95% CI 0.5-2.7), 1.5 (95% CI 0.9-2.6), 1.1 (95% CI 0.7-1.6) and 1.0 (95% CI 0.7-1.4) after exclusion of patients with distal deep vein thrombosis. in the duration of anticoagulation before study entry, we performed a multivariable analysis for patients with at least 6 months of anticoagulation, and this did not alter the strength of the association between shorter duration of anticoagulation and cancer risk (HR 1.38, 95% CI 1.07-2.00). The cancer risk was more than two-fold higher in patients with an initial proximal deep vein thrombosis and/or pulmonary embolism than in those with a distal deep vein thrombosis (HR 2.13, 95% CI 0.98-5.48).
Risk factors for cancer
Results from the sensitivity analysis performed with a multiple imputation approach were similar. The amount of missing data was low (five risk factors with, at most, 6% missing entries). Advancing age (HR per decade 1.61, 95% CI 1.28-2.02), duration of anticoagulation (HR per 1-month decrease 1.14, 95% CI 1.01-1.29) and the location of the initial thrombosis (HR 2.71, 95% CI 1.17-6.26) remained associated with the risk of cancer.
Recurrence of VTE and risk of cancer
The proportions of patients with recurrent VTE were similar among cancer and non-cancer patients (23% versus 25%). Figure 3 shows the time to cancer diagnosis in relation to VTE recurrence in the 62 individual patients. Recurrent VTE did not have a short-term effect on the risk of cancer, either in a crude analysis (HR for recurrent VTE as a time-varying covariate 1.31, 95% CI 0.71-2.43, P = 0.39) or in a model adjusting for patient's age, duration of anticoagulation, and location of initial thrombosis (HR for recurrent VTE as a time-varying covariate 0.97, 95% CI 0.52-1.90, P = 0.94). Thirty-one patients had a recurrent VTE within 4 months after study inclusion. There was no difference in cancer risk between patients with recurrent VTE early or later after inclusion, either in a crude analysis (HR for early versus later 1.02, 95% CI 0.34-3.00, P = 0.97) or in a model adjusting for the same risk factors as above (HR for early versus later 1.09, 95% CI 0.37-3.24, P = 0.87).
To further explore the association between recurrent VTE and time to future cancer development, we extracted, for each patient with recurrent VTE, a control group of similar patients without recurrence matched for age, sex and risk of recurrent VTE from the study data. In this matched cohort approach, which was adjusted for duration of anticoagulation, VTE recurrence was not associated with a significantly higher risk of cancer (HR 1.17, 95% CI 0.66-2.07, P = 0.58).
Discussion
The increased likelihood of detecting a malignant disease at the time of VTE diagnosis or during the months thereafter is well established [1] [2] [3] [4] [5] .
Our study addresses several clinically relevant aspects: first, whether the association between cancer and thrombosis continues to persist after long-term anticoagulation in patients who have thus far been asymptomatic; second, whether those thrombosis patients who develop cancer harbor special risk factors; and third, whether, if there is a diagnosis of cancer, its development follows specific patterns. The primary finding of our study is that the risk of cancer in patients with a first unprovoked VTE who completed anticoagulation is not higher than what would be expected in the general population. Overall, only 5% of thrombosis patients developed cancer during a median observation period of 8 years, and the probability of cancer was < 1% (0.7%, 95% CI 0.1-1.3%) during the first year after discontinuation of anticoagulation. Throughout the observation period, the SIR of patients with unprovoked VTE who developed cancer after their initial course of anticoagulation did not significantly exceed those of the sex-matched and age-matched general population. A systematic review reported that up to 10% of patients with unprovoked VTE will have a new diagnosis of cancer [18] . However, the finding was consistent only for the first 6-12 months after the acute VTE during a time when the majority of the patients were still on anticoagulant treatment [17] . More recently conducted trials showed lower rates of cancer ranging from 3.7% to 5%, but follow-up did not go far beyond 2.5 years [19] [20] [21] [22] . Also, in some older studies, data were mainly retrieved from hospital records, and the diagnoses 'deep vein thrombosis' and 'pulmonary embolism' were incorrectly coded in 10-20% of cases, as shown by subsequent analyses [5] . In contrast to those studies, our study population was very homogeneous and comprised only patients with a first unprovoked VTE who had all discontinued anticoagulation. We excluded patients who already had their VTE secondary to an already established cancer, and also those who developed cancer during anticoagulant treatment for VTE. Importantly, data on cancer diagnosis were collected during clinical visits or by direct patient contact.
The average age of our study cohort is lower than that of other VTE cohorts. This is explained by the exclusion of patients receiving long-term antithrombotic treatment, which also included aspirin, and the inclusion of women who had their VTE while they were using hormone contraceptives. According to recommendations of two Scientific and Standardization Subcommittees of the ISTH, these women should be regarded as having provoked thrombosis, as their risk of recurrent VTE is low [23] . However, we intentionally decided not to exclude these women, as a considerable proportion of cancers (6/62) occurred in this subgroup of patients. Also, restricting our analysis to a dataset excluding these 277 women did not change our overall findings (data not shown). Notably, for comparison of cancer risks, patients were age-matched and sex-matched to the general population, and the young average age is therefore taken into account by our statistical analysis.
The thrombogenicity of cancers varies, and certain types confer a particularly high risk of thrombosis. In a record-based case-control study from the USA including 1.2 million cancer cases and 200 000 controls and using linked Surveillance Epidemiology and End Results and Medicare data, the likelihood of cancer detection was highest during the first 12 months, but remained elevated for up to 6 years for certain tumor types, including colon cancer (odds ratio [OR] 1.2, 95% CI 1.1-1.4), pancreatic cancer (OR 1.3, 95% CI 1.2-1.5), and myeloma (OR 1.4, 95% CI 1.1-1.7) [6] . In our cohort, types of cancer were heterogeneous, with malignancies of the lung, colon, hematopoetic system and breast being among the most frequent. We did not observe a predominance of tumor types conferring a particularly high thrombotic risk, such as pancreatic, ovarian or brain cancers. Increasing age, which is one of the most important risk factors for cancer in the general population, was also the sole patientrelated independent risk factor in our population. The location of the initial VTE was also associated with a future diagnosis of cancer, with higher rates being seen in patients with proximal deep vein thrombosis or pulmonary embolism than in those with isolated distal deep vein thrombosis.
One-quarter of our patients developed a recurrent VTE during follow-up. Prandoni et al. reported a higher incidence of cancer in patients with recurrent idiopathic venous thrombosis than in patients without this condition [7] . In a study by Schulman et al., patients with recurrent VTE had a risk ratio of 1.3 (95% CI 1.0-1.6; P = 0.02) as compared with those without recurrence [5] . In contrast, we did not find a significant preponderance of cancer diagnoses among patients with recurrent VTE. The difference in study results can probably be explained by differences in the study population and methodology. First, our observation period started only at the end of initial anticoagulation therapy, a period of time during which the two other studies report the highest cancer incidence. Second, we treated recurrent VTE as a dynamic, time-varying variable to avoid immortal time bias. In an approach resembling a matched cohort study, we merely observed a non-significant trend for an elevated risk of cancer in patients with recurrent VTE as compared with those without recurrent VTE (HR 1.17, 95% CI 0.66-2.07). Failure to detect a difference in cancer rates between the two groups could also be attributable to lack of power, because of low cancer rates in our study. Also, importantly, an early recurrent VTE was not indicative of cancer development.
In our cohort, the likelihood of developing cancer was related to the duration of anticoagulation, whereby each month less of antocoagulation increased the risk of developing cancer by 30%. Two post hoc analyses of interventional trials evaluated the incidence of cancer according to different durations of vitamin K antagonist treatment. In an Italian cohort of unprovoked VTE, the incidence of cancer was not different between patients receiving 1 year and those receiving 3 months of anticoagulation, but the observation time was only 3.5 years on average [11] . In contrast, Schulman et al. reported a higher risk of cancer, with a risk ratio of 1.3, for the group assigned to 6 weeks of treatment than for the group assigned to 6 months of treatment (95% CI 1.1-1.6, P = 0.005) after adjustment for risk factors, including provoked or unprovoked VTE, and recurrence or non-recurrence of the VTE during follow-up. The mean follow-up in that study was 8.1 years after the incident VTE, and the difference between the groups in the likelihood of cancer did not become evident until the third year after the VTE [5] . Our patients had a similarly long follow-up, with a median of 8 years, which started after patients had stopped anticoagulation for a median of 7 months. Thus, our data complement the findings of Schulman et al. by also indicating an anticancer effect of anticoagulants that is apparent only at later time points after the initial VTE. A confounding effect of the variable duration of anticoagulation, which was based on the decision of the treating physician, cannot be ruled out. The association between shorter duration of anticoagulation and risk of cancer could also potentially reflect the time since cancer deleopment. Patients who developed cancer during anticoagulation were not included in our cohort, and this may have introduced selection bias. It is of note that all of our patients received vitamin K antagonists after an initial standard course of low molecular weight heparin. Hence, this observation cannot be extrapolated to patients treated with direct oral anticoagulants.
There are some additional strengths and limitations of our study. The study was performed in a large cohort of well-characterized patients with an objectively diagnosed unprovoked VTE only and a long follow-up. Our study was not designed to evaluate the risk of cancer, but rather the risk of recurrent VTE. However, diagnoses of cancer were well captured and documented, as patients were seen in person at the study center during prescheduled clinical visits. In a subset of patients, information on whether they had received a cancer diagnosis was obtained by questionnaire, but the return rate was very high (90%). The duration of anticoagulation was not standardized or controlled, but left to the discretion of the physician. We did not have information on tumor stage or histology. Thus, we could not assess a potential tendency for there to be a higher tumor stage at cancer diagnosis, which could be indicative of more aggressive tumor types in these patients. We have accounted for the dynamic nature of recurrent VTE as an event that develops during follow-up, and have minimized the impact of immortal time bias. Patients were excluded from the study if anticoagulant therapy was continued or if they used concomitant antiplatelet therapy, which may have biased our results through the selection of low-risk patients.
The results of our study have implications for counseling of patients and for screening recommendations. As patients with an acute unprovoked VTE are at a clinically relevant high risk of having an underlying cancer diagnosis, screening, at least to a basic extent, is generally recommended [24] . Our data show that thrombosis patients who did not have any signs or symptoms of malignancy during the period of anticoagulation had a low cancer risk. Thrombosis patients who completed anticoagulation and did not show any signs or symptoms of malignancy no longer had a specifically increased cancer risk. These patients should receive the same counseling on tumor screening and prevention as the general population. The inverse association between the duration of anticoagulation and the incidence of cancer is remarkable, and could be of clinical relevance. Therefore, it could be worth analyzing the large clinical trials on treatment of VTE comparing vitamin K antagonists with direct oral anticoagulants from this particular perspective.
